60 degrees pharma withdraws covid phase iib ind, will resubmit pending assessment of ability to meet fda requirements

Washington, sept. 18, 2023 (globe newswire) -- 60 degrees pharmaceuticals, inc. (“60p”) (nasdaq: sxtp), specialists in developing and marketing medicines for infectious diseases, today announced that 60p australia pty ltd, a majority-owned subsidiary of 60p, has withdrawn its investigational new drug (ind) application for aclr8-lr, a phase iib study of the use of tafenoquine in treating covid-19, and intends to submit a new ind in the fourth quarter.
SXTP Ratings Summary
SXTP Quant Ranking